Haemodiafiltration (HDF) is an advanced form of dialysis that combines the principles of hemodialysis and hemofiltration to provide superior clearance of toxins, particularly middle and large molecular-weight substances. It is increasingly recognized as an enhanced dialysis modality for selected patients with chronic kidney failure.

At International Modern Hospital, HDF is offered as part of an advanced nephrology service for patients who may benefit from improved dialysis efficiency, better cardiovascular stability, and enhanced long-term outcomes. The therapy is delivered under strict clinical protocols using high-flux membranes and ultrapure dialysis water.

Unlike conventional hemodialysis, which relies primarily on diffusion, HDF incorporates convection-based clearance. This allows for more effective removal of inflammatory mediators and uremic toxins associated with cardiovascular complications, chronic inflammation, and dialysis-related amyloidosis.

HDF is particularly beneficial for patients experiencing dialysis-related symptoms such as fatigue, hypotension, muscle cramps, or inadequate toxin clearance on standard hemodialysis. It may also support better blood pressure control and improved overall tolerance to dialysis sessions.

Before initiating HDF, patients undergo detailed clinical evaluation, including vascular access assessment, cardiovascular stability, and dialysis adequacy review. Nephrologists determine suitability and prescribe individualized treatment parameters to maximize benefit and safety.

IMH’s dialysis infrastructure supports online HDF, ensuring precise fluid balance and high-quality replacement fluid generation. Continuous monitoring during sessions ensures patient comfort and early identification of complications.

HDF is integrated into the broader kidney care pathway at IMH, with ongoing monitoring of anemia management, bone-mineral metabolism, nutritional status, and cardiovascular health. Education and counseling help patients understand treatment goals and actively participate in their care.

By offering HDF, IMH provides eligible patients with access to next-generation dialysis therapy aimed at improving survival, symptom control, and quality of life.